Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties.
Bepridil is an anti-anginal agent with a novel chemical structure. Its main pharmacological effects are an increase in coronary blood flow, a reduction in myocardial oxygen demand, reduction in cardiac work, primarily by a decrease in after-load and a dose-dependent negative chronotropic effect, and anti-arrhythmic properties. These are mainly due to a calcium-antagonistic action. There is evidence that fast sodium channels in heart muscle are also inhibited. Trials have shown that bepridil is effective in the prophylactic treatment of various forms of angina pectoris and accompanying arrhythmias. Pharmacokinetic data justify once-daily administration. The evidence suggests that bepridil is generally well tolerated. This paper reviews already published studies and the results of recent investigations on the pharmacological and clinical efficacy of bepridil.
J S
JS
Alpert
P
P
Coumel
K
K
Greeff
D M
DM
Krikler
W J
WJ
Remme
E
E
Schönbaum
C W
CW
Verduyn
D000787:Angina Pectoris / Q000188:drug therapy*; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D015764:Bepridil; D002118:Calcium / Q000378:metabolism; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D011759:Pyrrolidines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012964:Sodium / Q000378:metabolism; D013045:Species Specificity; D013997:Time Factors
D007473:Ion Channels; D011759:Pyrrolidines; D015764:Bepridil; D012964:Sodium; D002118:Calcium